EVIDENCE BASED MANAGEMENT OF H-PYLORI
Short Explanation Of The Chosen Complaint
When the H. pylori bacilli infect any part of the gastrointestinal tract, Helicobacter pylori (H. pylori) infection results. Both duodenal and stomach ulcers are frequently caused by H. pylori infection. A spiral-shaped, gram-negative bacteria with sheathed flagella known as H. pylori has been found in at least 90% of people with duodenal ulcers (Cash et al., 2021).
Furthermore, this bacterium has been found in 40% and 70% of people with stomach ulcers (Cash et al., 2021). The anticipated lifetime risk for developing PUD in those with H. pylori infection is around 15%. (Wang et al., 2015). At the same time, gastric cancer continues to be the third-leading cause of cancer-related deaths worldwide, and H. pylori infection is thought to be responsible for 74.7% of all non cardia gastric cancer cases (Wang et al., 2015). Nevertheless, H. pylori infection is also seen in people with dyspepsia without ulceration and asymptomatic gastritis; however, eliminating the organism does not appear to affect these patients’ symptoms.
Research suggests that H. pylori disease may affect a sizable, excessive number of people globally. However, because there are not any obvious indications or symptoms of an active disease, most are unaware that they have this condition. According to estimates, the annual incidence of peptic ulcers can range from 0.1% to 1.8%. (Cash et al., 2021). The prevalence of ulcers in
1% of the population has a yearly pylori infection (Cash et al., 2021). Ulcer formation is primarily triggered by two pathophysiological factors: diminished mucosal defense and increased acid production (Berkowitz, 2020). As was previously noted, one of the most typical causes of ulcers is H-pylori infection. H. pylori, in particular, causes ulcers by both of these mechanisms: it harms the mucosal membrane and triggers an inflammatory response that increases acid output.
Moreover, H. pylori infections continue to be spread through the oral-fecal and oral-oral routes, and infection rates in underdeveloped countries with contaminated water supplies are close to 100%. (Berkowitz, 2020). At least 75% of people over 50 who live in affluent countries with clean water sources have contracted an infection at some point (Berkowitz, 2020). The risk of relapse is significantly altered by eliminating the organism. Hence, socioeconomic variables like living in an overcrowded home, lacking access to clean water, living in a developing nation, or sharing a home with someone who has had Helicobacter pylori infection in the past all increase the risk of contracting the condition (Diaconu et al., 2017). To treat H. pylori infections, there are several antibiotic combinations and evidence-based management strategies that work.
System Evaluation Is Required
Since H. pylori infection continues to be the most common and chronic bacterial infection globally, obtaining an accurate, thorough, and essential review of the systems is crucial. According to the most recent research, H. pylori infection not only endangers the health of the digestive system as a whole but also impacts other systems like cardiovascular, hematological, neurological, and metabolic disorders.
According to Diaconu et al. (2017), it is well-known that H. pylori can cause iron deficiency anemia, vitamin B12 insufficiency, and idiopathic thrombocytopenic purpura. Furthermore, according to the most recent research, children with type 1 diabetes are at an increased risk of developing H. pylori infection, particularly in cases where the disease has been present for longer (Bazmamoun et al., 2016). An additional study analysis to take into account
Focuses on the connection between preeclampsia and Helicobacter pylori infection. The results of this clinical trial demonstrate aberrant Doppler velocimetry in the uterine arteries, suggesting that H. pylori infection may interfere with placental development and increase the chance of developing preeclampsia (Di Simone et al., 2017). The connection between metabolic syndrome problems and H. pylori data further supports infection. Helicobacter pylori infection has a strong correlation with greater triglycerides, body mass index, homeostatic model assessment of insulin resistance (HOMA-IR), systolic blood pressure, and reduced HDL, according to Upala et al. (2016).
Consequently, H. pylori infection mainly occurs in the gastrointestinal system; nevertheless, relevant evidence-based research swiftly suggests the link of H. pylori with varied illnesses outside the gastrointestinal tract. Undoubtedly, this bacteria causes a low-grade inflammatory phase, triggers molecular mimicry mechanisms, and obstructs the absorption of nutrients and medications, likely having an impact on the occurrence or development of a variety of illnesses (Roubaud Baudron et al., 2013). As a result, screening for H. pylori infection is beneficial when it considers a variety of systems collectively rather than just the gastrointestinal system. The evaluation of the study material that is described above offers a novel way to look at the relationship between H. pylori infections and several body systems.
What Could Be Found During a Physical Assessment for This Complaint?
The clinical signs of Helicobacter pylori infection range from asymptomatic gastritis to gastrointestinal cancer; however, they are not usually obvious. The way H. pylori affects people varies. Not everyone with H. Pylori infection goes on to get ulcers. On the one hand, H. pylori cause chronic atrophic gastritis and, in certain cases, stomach cancer by causing intestinal metaplasia in the stomach (Diaconu et al., 2017). On the other side, Peptic Ulcer Disease (PUD) is caused by H. pylori, which modifies stomach output and causes tissue damage (Diaconu et al., 2017). In summary, a variety of factors, including genetics, the location and kind of PUD, environment, and food, affect how the body reacts to H. pylori and its clinical manifestations.
Numerous studies indicate that there are no appreciable differences between patients with H. pylori infection and those who do not have the bacterium when it comes to the specific clinical manifestations of this infection, including recurrence of symptoms like nausea, vomiting, pain, heartburn, or diarrhea (Santacroce & Bhutani, 2021). There is no concrete evidence to support a link between the symptoms of H pylori-related gastritis, abdominal discomfort, or dyspeptic symptoms from other disorders (Santacroce & Bhutani, 2021).
However, specific medical problems where H. pylori infection is still the main contributing component may show certain clinical signs and symptoms. For instance, a continuous H. pylori infection is the most frequent cause of duodenal ulcers. Consequently, the symptoms and indicators of this particular illness include scorching and gnawing pain in the epigastrium.
Tenderness in the left upper quadrant of the abdomen and at the epigastrium 2-3 hours after meals, alleviation from food and antacids, and mildly hyperactive bowel sounds (Fitzgerald, 2017).
Moreover, persistent type B (antral) gastritis that is non-erosive is primarily brought on by an
Infected by pylori. The usual presenting signs and symptoms include nausea, burning, and upper abdominal pain without reflux symptoms (Fitzgerald, 2017). Primary-care practitioners frequently deal with patients who have dyspepsia, which can result from a variety of circumstances. Nevertheless, research indicates that 20% to 60% of people with functional dyspepsia have gastritis caused by Helicobacter pylori (Diaconu et al., 2017).
- Pylori-Related Differential Diagnoses and the Justification for Each
This condition encompasses a wide range of circumstances that intensify inflammatory changes in the stomach mucosa. While many different illnesses share some common overall clinical symptoms, they differ in their unique histologic characteristics. Moreover, this condition can be classified into erosive and non-erosive forms (which are frequently triggered by Helicobacter pylori) (El-Nakeep, 2020).
Acid Reflux Disease:
PUD is a limited ulceration of the GI mucosa that occurs in regions that are vulnerable to acid and pepsin. The patients’ prior ulcer records typically predict predicted behavior and a pathological likelihood of future ulcers. The process appears to involve the combination of acid production, pepsin secretion, H. pylori bacterial infection, and mucosal defense systems, even if the precise processes of ulcer development are still not fully understood (Cash et al., 2021).
Lymphoma of the gastric mucosa-associated lymphoid tissue (MALT):
Data from studies illuminate the pathogenetic chain of stomach lymphoma. Gastritis brought on by H. pylori has been shown to be the main cause of MALT in the gastric mucosa. Undoubtedly, the development of MALT in the stomach mucosa is a pathogenic sign of H. pylori infection (Zullo et al., 2014). On the other hand, every infected person has a high implied risk of developing stomach MALT lymphoma, especially over the course of a protracted infection (Zullo et al., 2014).
A comparison and contrast of two H. pylori clinical guidelines
Clinical Guidelines are made to provide doctors with the most recent evidence-based advice on how to manage any condition. The two clinical guidelines for the management of H. Pylori for this assignment include suggestions from the American College of Gastroenterology and the American Academy of Family Physicians.
Both recommendations suggest testing for H. pylori infection in all patients with active peptic ulcer disease (PUD), a history of PUD, (MALT) lymphoma, or a history of endoscopic resection of early gastric cancer (EGC) (American College of Gastroenterology, 2017; American Family Physicians, 2015). Continual non-endoscopic testing for H. pylori infection is the recommended course of action for anyone under 60 who exhibits dyspepsia symptoms without any other alarming symptoms (American College of Gastroenterology, 2017; American Family Physicians, 2015). Both recommendations state that retesting is required to confirm the complete eradication of the virus anytime H. pylori is identified and treated. Urea breath testing, fecal antigen testing, or biopsy-based testing should be used to ensure full eradication at least four weeks after the completion of antibiotic treatment and one to two weeks after the cessation of PPI use (American College of Gastroenterology, 2017; American Family Physicians, 2015).
Although most of the analyzed data was comparable across the two standards, several discrepancies were noted. On the one hand, the American College of Gastroenterology recommends testing for H. pylori infection in all patients with unexplained iron deficiency (ID) anemia despite a thorough assessment (2017). However, the American Academy of Physicians recommends H. Pylori testing for ID patients only if dyspepsia is present (2015). The quadruple bismuth therapy, which includes bismuth, tetracycline, and nitroimidazole continuously for 10–14 days, is advised as the first line of treatment (American College of Gastroenterology, 2017). The American Academy of Physicians asserts that the non-bismuth-based quadruple therapy has the highest success rate for eliminating H. pylori, even though they acknowledge that alternative regimens may be utilized (2015). Quadruple bismuth therapy is not considered first-line therapy, according to the American Academy of Physicians, but it may be used as such in regions with significant resistance or when the cost is a crucial factor (2015).
Evidence-Based Treatment Strategy
The most well-known and cost-effective way of identifying H. pylori is stool antigen testing, especially when used in conjunction with a clinical presentation that is compatible with other illnesses, according to numerous relevant research assessments. Recent evidence-based literature also indicates that the fast urease test is the preferred diagnostic test for H. Pylori and that endoscopy plus biopsy is the most precise test. For instance, data from 99 comparisons were used in a relevant Cochrane report analysis to investigate the diagnostic efficacy of various non-invasive tests to identify any infection involving the H. Pylori bacterium (Fischbach & Malfertheiner, 2018). The study’s findings support the claim that breath tests are more reliable at making diagnoses than serology tests; however, stool antigen detection techniques are similarly accurate (Fischbach & Malfertheiner, 2018).
Undoubtedly, the organism makes urease, which breaks down urea into ammonia and CO2. By neutralizing H+ ions in gastric acid, urease enables the organism to adjust pH in its immediate environment in the stomach (Fitzgerald, 2017). As a result, urea breath testing is a beneficial diagnostic approach when seeking to establish the existence of H. pylori infection; however, it is usually more expensive than the stool antigen test. Crucial data information reminds us that fecal and urea breath testing may produce a false negative if a PPI is currently being used. The patient should ideally stop taking PPI two weeks before these testing (American College of Gastroenterology, 2017).
Similar options exist for serological testing for H. pylori, with the drawback that titers might persist for years even after effective therapy. Nevertheless, 12 to 18 months after receiving treatment, 50% of those who underwent a serological test had undetectable titers (Fitzgerald, 2021).
To check for the existence of H. Pylori, stomach ulcers, or malignancies, endoscopy with biopsy tests should be used on persons older than 50 who exhibit new-onset PUD signs and symptoms (American College of Gastroenterology, 2017).
Plan for Evidence-Based Management
The elimination of the H. Pylori bacteria in afflicted people is the empirical pharmaceutical treatment for H. Pylori. An antibiotic and an antisecretory drug combination is the current pharmaceutical strategy. Moreover, phytomedicines and probiotics are being used to improve the eradication of H. pylori despite the fact that the mode of action is not clearly understood (Yang et al., 2014). The recommendations for first-line therapy, second-line therapy, third-line therapy, and subsequent therapy vary based on the geographic region. Guidelines for the management of H. pylori infection are still being developed. Current evidence-based recommendations state that the first-line treatment for H. pylori infection is typically a triple therapy consisting of a PPI, two antibiotics (clarithromycin and amoxicillin/metronidazole), and a PPI. Clarithromycin (Biaxin) 500mg BID plus amoxicillin (1 g BID) or metronidazole (Flagyl) 500mg BID if allergic to amoxicillin will therefore be included in the usual triple therapy for H. Pylori for a period of 14 days, followed by a PPI for a period of 4 to 8 weeks.
Moreover, because of its great efficacy, safety, and tolerance, bismuth-containing quadruple treatment (BQT) is authorized as a first-line optional therapy for eliminating H. pylori in regions with high or low clarithromycin resistance (Hu et al., 2020). This 12-day treatment of bismuth subsalicylate tablet 525 mg four times daily, metronidazole 250 mg four times daily, tetracycline cap 500 mg four times daily, and a PPI or ranitidine 150 mg twice daily makes up the quadruple therapy regimen. Following therapy and failure therapies regimens for H. Pylori are available for clinical use, although it differs in prognostics and eradication success outcomes.
Education of Patients
It is essential to provide H. pylori patients with education about appropriate pharmaceutical care in order to prevent problems or antibiotic resistance. Inform the customer how to take medicine as directed. Even if the signs and symptoms have subsided, do not stop taking the prescription. It is also important to take into account specific pharmaceutical education. For instance, tell the patient that clarithromycin or metronidazole may cause a metallic aftertaste in the mouth.
Furthermore, probiotic and vitamin usage education needs to be provided.
Probiotics as a supplement to triple therapy have been shown to increase its efficacy and decrease the frequency of therapy-related diarrhea, which could sustain and restore the gut microbiota in patients of all ages receiving treatment for various diseases.
Pylori (Hu et al., 2020). (Hu et al., 2020). Also, an RCT investigation assessed the effect of vitamin supplements and H. pylori therapy (C&E) on the occurrence and death of stomach cancer. This study indicated that vitamins C and E are recorded to generate an inhibitory effect on H. pylori intensity and neutrophilic activity, which benefit the eradication of H. pylori 2019 (Li et al.)
Also, imparting knowledge on lifestyle changes, avoiding drinking and smoking due to potential drug interactions, or worsening of H. Pylori infection symptoms. Avoid caffeine, spicy foods, chocolate, and peppermint since these may cause your stomach to produce more acid (Cash et al., 2021). Reduce salt intake as well, as research indicates that it makes H. pylori-induced inflammation worse (Haley & Gaddy, 2016).
Lastly, education concerning when to notify the primary care provider about worsening symptoms is also crucial.
Relief should be possible with a therapeutic trial of dietary adjustments combined with the proper pharmaceutical treatment. After the therapy has run its course, there must be follow-up appointments. It is empirical to repeat the breath test to ensure that H. Pylori has been eliminated. Other therapies should be taken into consideration if the previous therapy proved ineffective. The choice of regimen, the patient’s compliance with a multi-drug regimen with a variety of adverse effects, and the sensitivity of the H. pylori infection are the key factors in determining the efficacy of H. pylori eradication.
The combination of medicines used to treat the H. pylori strain (Chey et al., 2017). In essence, the clinician must request a urea breath test, fecal antigen test, or biopsy-based testing at least four weeks after the conclusion of antibiotic therapy and after 1-2 weeks of discontinuing PPI use to determine the eradication of an H. Pylori infection (Chey et al., 2017).
When signs of hemorrhage, penetration, perforation, or stomach outlet obstruction exist, a client needs to be seen by a surgeon and a gastroenterologist and admitted to the hospital. A doctor must be referred for an endoscopy or breath test to assess H. Pylori in patients with recurrences or refractory sickness.
a case study
M.M., a 64-year-old Hispanic woman, presents to the clinic complaining of moderately intense, intermittent, burning/gnawing epigastric discomfort that has been present for four weeks. The patient disclaimed having melena, hematochezia, or hematemesis symptoms and signs. Her peptic ulcer condition was a major aspect of her medical history. M.M. recalls making the trip to Camden City from a small hamlet in Colombia around two months ago. Living with her entire extended family M.M. M.M. recalled that her husband displayed the same signs and symptoms. She also acknowledged having previously taken an over-the-counter painkiller that had acetaminophen, aspirin, and caffeine. Bowel sounds were audible upon examination in each of the four quadrants. Above the epigastrium, there was, however, a slight soreness. Conclusion
Nurse Practitioners are key clinicians in many healthcare settings in supporting the H. Pylori diagnosis and treatment based on current evidence-based research. This research provided the management of H. Pylori based on current guidelines to treat and eradicate the illness successfully. In short, this research highlighted the available therapies, together with the regimen aims for the treatment of H. Pylori, focusing on easing pain, and discomfort, promoting healing, minimizing complications, and limiting recurrences while minimizing the expense and adverse effects of treatment.
American College of Gastroenterology. (2017). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection, American Journal of Gastroenterology. 112(2), 212-239. 10.1038/ajg.2016.563
American Family Physicians. (2015). Diagnosis and Treatment of Peptic Ulcer Disease and H. pylori Infection., National Center for Biotechnology Information. 91(4), 236–242.
Bazmamoun, H., Rafeey, M., Nikpouri, M., & Ghergherehchi, R. (2016). Helicobacter Pylori Infection in Children with Type 1 Diabetes Mellitus: A Case-Control Study. Journal of research in health sciences, 16(2), 68–71.
Berkowitz, A. (2020). Clinical Pathophysiology of Systems. MedMaster, Inc.
Cash, J. C., Glass, C. A., & Mullen, J. (2021). Family practice guidelines. Springer Publishing Company.
Chey, W., Leontiadis, G., Howden, C., Moss, S. (2017). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection, American Journal of Gastroenterology: 112(2), 212-239 doi: 10.1038/ajg.2016.563
Diaconu, S., Predescu, A., Moldoveanu, A., Pop, C. S., & Fierbințeanu-Braticevici, C. (2017).
Helicobacter pylori infection: old and new. Journal of medicine and life, 10(2), 112–117.
Di Simone, N., Tersigni, C., Cardaropoli, S., Franceschi, F., Di Nicuolo, F., Castellani, R., Bugli, F., de Waure, C., Cavaliere, A. F., Gasbarrini, A., Sanguinetti, M., Scambia, G., & Todros,
- (2017). Helicobacter pylori infection contributes to placental impairment in preeclampsia: basic and clinical evidences. Helicobacter, 22(2), 10.1111/hel.12347.
El-Nakeep, S. (2020). Acute Gastritis. Medscape Physician. https://emedicine.medscape.com/article/175909-overview.
Fischbach, W., & Malfertheiner, P. (2018). Helicobacter Pylori Infection. Deutsches Arzteblatt international, 115(25), 429–436. https://doiorg.felician.idm.oclc.org/10.3238/arztebl.2018.0429
Fitzgerald, M. A. (2017). Nurse practitioner certification examination and practice preparation.
F.A. Davis Company.
Haley, K. P., & Gaddy, J. A. (2016). Nutrition and Helicobacter pylori: Host Diet and Nutritional Immunity Influence Bacterial Virulence and Disease Outcome. Gastroenterology research and practice, 2016, 3019362. https://doi.org/10.1155/2016/3019362
Hu, Y., Zhu, Y., & Lu, N. H. (2020). Recent progress in Helicobacter pylori treatment. Chinese medical journal, 133(3), 335–343.
Li W.Q, Zhang Y, Ma JL, Li., Zhang L., Zhang Y., et al. (2019). Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ 2019; 366:l5016.doi: 10.1136/bmj.l5016
Roubaud Baudron, C., Franceschi, F., Salles, N., & Gasbarrini, A. (2013). Extragastric diseases and Helicobacter pylori. Helicobacter, 18 Suppl 1, 44–51.
Santacrose, L., & Bhutani, M. S. (2021). Helicobacter Pylori Infection Clinical Presentation.
Emedicine . https://emedicine.medscape.com/article/176938-clinical – :~:text=No definite evidence demonstrates a,pylori eradication results in sustained.
Upala, S., Jaruvongvanich, V., Riangwiwat, T., Jaruvongvanich, S., & Sanguankeo, A. (2016).
Association between Helicobacter pylori infection and metabolic syndrome: a systematic review and meta-analysis. Journal of digestive diseases, 17(7), 433–440. https://doi.org/10.1111/1751-2980.12367
Wang, Y. K., Kuo, F. C., Liu, C. J., Wu, M. C., Shih, H. Y., Wang, S. S., Wu, J. Y., Kuo, C. H.,
Huang, Y. K., & Wu, D. C. (2015). Diagnosis of Helicobacter pylori infection: Current options and developments. World journal of gastroenterology, 21(40), 11221–11235. https://doi-org.felician.idm.oclc.org/10.3748/wjg.v21.i40.11221
Yang JC, Lu CW, Lin CJ. (2014). Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterology; 20(18): 5283-5293
Zullo, A., Hassan, C., Ridola, L., Repici, A., Manta, R., & Andriani, A. (2014). Gastric MALT lymphoma: old and new insights. Annals of gastroenterology, 27(1), 27–33.
We’ll write everything from scratch
Discuss the drug therapy used in the treatment of H. pylori to alleviate symptoms, promote healing, prevent complications, and prevent recurrence.
2 peer reviewed references
"Place your order now for a similar assignment and have exceptional work written by our team of experts, guaranteeing you A results."